CenterPoint Energy, Inc. (CNP) is slated to report second-quarter 2024 results on Jul 30 before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 7.84%. The company holds a four-quarter average earnings surprise of 3.13%. Let's discuss the factors that are likely to be reflected in the upcoming quarterly results. Factors to Note The majority of the company's service territories experienced warmer-than-normal temperature patterns for most of the second quarter. Suc ...

CenterPoint Energy (CNP) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 30 ...

NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CenterPoint Energy, Inc. (“CenterPoint” or the “Company”) (NYSE: CNP).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether CenterPoint and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] O ...

NEW YORK, July 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CenterPoint Energy, Inc. ("CenterPoint" or the "Company") (NYSE: CNP). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether CenterPoint and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.[Click here for information about joining the class action]On July 8, 202 ...

文章核心观点 - 2024年7月8日,1级飓风贝尔登陆德克萨斯州,导致约220万CenterPoint能源公司的客户停电 [1][2] - 6天后,休斯顿地区仍有27万户家庭和企业停电 [2] - 德克萨斯州州长格雷格·阿博特要求对CenterPoint的应对措施进行调查,称CenterPoint没有在风暴来临前部署足够的工人 [2] - 此消息公布后,CenterPoint股价下跌6.67%,每股下跌2.02美元 [2] 公司概况 - CenterPoint Energy, Inc.是一家能源公司,主要从事电力和天然气输配业务 [1] - 公司股票代码为NYSE: CNP [1] 事件影响 - 飓风贝尔导致CenterPoint大规模停电,影响了约220万客户 [2] - 6天后仍有27万户家庭和企业停电,引发州长的批评和调查 [2] - 此事件导致公司股价下跌6.67% [2]

Investors interested in Utilities stocks should always be looking to find the best-performing companies in the group. CenterPoint Energy (CNP) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out. CenterPoint Energy is a member of the Utilities sector. This group includes 105 individual stocks and currently holds a Zacks Sector Rank of #2. The Zack ...

文章核心观点 - 韩国护肤品牌CNP Laboratory在美国亚马逊市场受到关注 [1] - CNP的旗舰产品Propolis Lipcerin™在TikTok上走红,带动了在美国亚马逊的上市 [1] - CNP Propolis Lipcerin™在亚马逊美国市场的唇膏类别中排名第一 [2][3] 公司概况 - CNP Laboratory由来自Cha和Park皮肤科诊所的皮肤科医生创立,于2000年成立 [1] - 公司旨在提供安全有效的家用护肤解决方案,依托多年的临床经验和精准配方 [1] - CNP在韩国已经成为领先的护肤品牌,获得了多个行业和消费者奖项 [4] - 2014年,LG Household & Health Care收购了CNP Cosmetics,使其在皮肤护理市场上更加领先 [5] 产品表现 - CNP的Propolis Ampoule产品自2005年推出以来,销量已超过600万瓶,在韩国Olive Young连锁店的在线销售中一直排名第一 [2] - CNP Propolis Lipcerin™以其独特的功效在亚马逊美国市场的唇膏类别中排名第一 [2][3]

Houston, TX, June 26, 2024 (GLOBE NEWSWIRE) --     Date: July 30, 2024   Time:  7:00 a.m. Central time or 8:00 a.m. Eastern time   Listen via internet:  http://investors.centerpointenergy.com/   Click "Investors", and click the link "CenterPoint Energy, Inc. Second Quarter 2024 Earnings Conference Call"   As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natu ...

文章核心观点 - 公司的TransCon CNP(navepegritide)在治疗2-10岁儿童型矮小症患者1年后,在生活质量和身体功能方面显示出与安慰剂相比的显著改善[1][2][3] - 这些改善不仅仅可以用线性生长的变化来解释,支持TransCon CNP可能具有超越线性生长的直接治疗效果[1][2] - TransCon CNP作为首个在治疗型矮小症患者中显示出在健康相关生活质量指标方面与安慰剂相比有统计学显著改善的实验性药物,有望满足这一疾病健康和生活质量并发症的治疗需求[3] 关键数据总结 - 在100μg/kg/周的剂量组,与安慰剂相比,患者在日常生活功能(p=0.047)和情感健康(p=0.045)等指标上有显著改善[4] - 5岁及以上患者的SF-10身体功能汇总评分也有显著改善(p=0.002)[4] - 整个试验人群在100μg/kg/周剂量下52周的生长结果与随机期间该剂量组一致[4] - 未观察到新的安全信号,也未报告与研究药物相关的严重不良事件[4] - 大部分不良事件为1-2级,注射部位反应发生率较低[5]

Artistic Operations Shares of CenterPoint Energy (NYSE:CNP) have been a modest performer over the past year, rising just 7%, and lagging the broader market as elevated interest rates have weighed on utility valuations. However, shares have been rising steadily since reporting solid Q1 earnings and sit near a 52-week high. I last covered CenterPoint in March, rating shares a “buy,” and since that recommendation, CNP has returned 12%, ahead of the market’s 6% rally. I remain bullish Seeking Alpha In the ...